2. Search Result
Search Result
Results for "

orlistat

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0218
    Orlistat
    Maximum Cited Publications
    26 Publications Verification

    Tetrahydrolipstatin; Ro-18-0647

    		 Fatty Acid Synthase (FASN) Apoptosis Metabolic Disease Cancer
    Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity . Anti-atherosclerotic effect .
    Orlistat
  • HY-B0218R
    Orlistat (Standard)
    Maximum Cited Publications
    26 Publications Verification

    Tetrahydrolipstatin (Standard); Ro-18-0647 (Standard)

    		 Reference Standards Fatty Acid Synthase (FASN) Apoptosis Metabolic Disease Cancer
    Orlistat (Standard) is the analytical standard of Orlistat. This product is intended for research and analytical applications. Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity . Anti-atherosclerotic effect .
    Orlistat (Standard)
  • HY-14423
    Velneperit
    1 Publications Verification

    S2367

    		 Neuropeptide Y Receptor Neurological Disease Metabolic Disease
    Velneperit (S-2367) is an orally active neuropeptide Y (NPY) Y5 receptor antagonist that can penetrate the blood-brain barrier. Velneperit inhibits the appetite-stimulating and metabolism-inhibiting effects mediated by NPY. Velneperit selectively improves diet-induced obesity in mice. Velneperit enhances the expression of fear acutely by removing the inhibition of CeA Drd2 neurons. Velneperit can be used for the study of obesity .
    Velneperit
  • HY-W709047
    Orlistat impurity-M3

    		Drug Metabolite Metabolic Disease
    Orlistat impurity-M3 is a Orlistat (HY-B0218) degradation product. Orlistat is a well-known irreversible inhibitor of pancreatic and gastric lipases .
    Orlistat impurity-M3
  • HY-B0218S
    Orlistat-d3

    Tetrahydrolipstatin-d3; Ro-18-0647-d3

    		 Isotope-Labeled Compounds Fatty Acid Synthase (FASN) Apoptosis Metabolic Disease
    Orlistat-d3 is a deuterated labeled Orlistat . Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity .?Anti-atherosclerotic?effect .
    Orlistat-d3
  • HY-172298
    (R,S,S,S)-Orlistat

    (R,S,S,S)-Tetrahydrolipstatin; (R,S,S,S)-Ro-18-0647

    		 Fatty Acid Synthase (FASN) Infection
    (R,S,S,S)-Orlistat is a stereogenic derivative of orlistat (tetrahydrolipstatin; THL) (HY-B0218). (R,S,S,S)-Orlistat inhibits three Mycobacterium tuberculosis lipid esterases, Ag85C (KI: 16.43 μM), Rv3802 (EC50: 16.2 nM), and Pks13-TE .
    (R,S,S,S)-Orlistat

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: